Can Lilly's Olumiant Prickle Xeljanz In India?
Executive Summary
Lilly’s Olumiant has hit the Indian market, upping the level of competition in a rheumatoid arthritis sector that already includes the fellow JAK inhibitor Xeljanz from Pfizer and at least half a dozen biosimilar versions of Humira, among other products. But could pricing cloud Olumiant’s uptake?
You may also be interested in...
Rheumatoid Arthritis Data Position Filgotinib Ahead Of Competition, But It's Playing Catch-Up
Prospects rose for Galapagos and partner Gilead's JAK1 inhibitor with impressive Phase III FINCH 2 data in patients with moderate-to-severe rheumatoid arthritis.
Here’s What Competition Looks Like In India’s Humira Biosimilars Market
Competition may be just readying to jump in and gnaw into Humira’s share in Europe later this year, but the Indian market for biosimilar adalimumab already has more than half a dozen players, with distinct pricing characteristics. Scrip takes a peek into the competitive market.
Lilly Prices Olumiant For JAK Battle, But Misses Approval For Higher Dose
Lilly priced its now-approved Olumiant (baricitinib) to fight for US market share versus well-known rheumatoid arthritis therapies, undercutting Humira by 60% and Pfizer's established JAK inhibitor Xeljanz by 50%.